Not exact matches
We will develop multiplexed assays that will allow us to
measure multiple proteins at a time in human samples, thus
increasing the speed with which we can test candidate
biomarkers.
In future studies, it will be important to
measure the
biomarker at several time points to determine whether levels of the
biomarker increase as the disease progresses, Apte said.
In addition, results from a recently developed
biomarker assay that was designed to
measure levels of SMN protein in the cerebral spinal fluid (CSF), showed time - and dose - dependent
increases in SMN protein levels in SMA children treated with ISIS - SMNRx from both single - and multiple - dose studies.